Significant benefit seen in Phase III trial of experimental drug for kidney disease

In a clinical trial of patients with chronic kidney disease, an experimental drug significantly reduced albuminuria—albumin in urine, a sign of kidney damage—for 50% of participants. When the experimental drug was paired with a standard-care medication, 70% of participants reportedly experienced a significant reduction in albuminuria.

Leave A Comment

Your email address will not be published. Required fields are marked *